Recently, GPN01530, a globally innovative FAP target radionuclide conjugation drug independently developed by Yuanda Pharmaceutical, was officially approved by the US FDA to conduct phase I/II clinical research to diagnose solid tumors.

Recently, GPN01530, a globally innovative FAP target radionuclide conjugation drug independently developed by Yuanda Pharmaceutical, was officially approved by the US FDA to conduct phase I/II clinical research to diagnose solid tumors.